Document is current
Any future updates will be listed below
-
Authors
Hayanga, J. W. Awori
Song, Tae
Durham, Lucian
Garrison, Lawrence
Smith, Deane
Molnar, Zsolt
Scheier, Joerg
Deliargyris, Efthymios N.
Moazami, Nader
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04391920 at ClinicalTrials.govDocuments that mention this clinical trial
Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry
https://doi.org/10.1186/s13054-023-04517-3
-
Funding
Funding for this research was provided by:
CytoSorbents Inc. US Monmouth Junction NJ, USA
- License Information
-
More Information
Article History
Received: 2 March 2023
Accepted: 2 June 2023
First Online: 19 June 2023
Declarations
:
: Prior to the collection of de-identified patient data from medical records and entry into the registry database, all participating US centers obtained written notice of approval from their respective Institutional Review Boards. In accordance with Good Clinical Practices (GCP) guidelines and applicable regulatory and institutional requirements, written informed consent from study participants was not required.
: JS and ZM are full time employees of CytoSorbents Europe GmbH. END is a full-time employee of CytoSorbents Inc. US Monmouth Junction NJ, USA. The other authors state that they have no conflicts of interest.
